Patents by Inventor Robert M. Scarborough

Robert M. Scarborough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoassays for human and canine brain natriuretic peptide
    Publication number: 20030109430
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Application
    Filed: July 9, 2001
    Publication date: June 12, 2003
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Integrin antagonists
    Patent number: 6552079
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Oxindole inhibitors of factor Xa
    Patent number: 6548517
    Abstract: Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: April 15, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Charles K. Marlowe, Kim A. Kane-Maguire, Bing-Yan Zhu, Robert M. Scarborough
  • Benzamide inhibitors of factor Xa
    Publication number: 20030069250
    Abstract: Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian Factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: April 1, 2002
    Publication date: April 10, 2003
    Inventors: Bing-Yan Zhu, Penglie Zhang, Erick A. Goldman, Zhaozhong Jon Jia, Shawn Bauer, Wenrong Huang, John Woolfrey, Robert M. Scarborough
  • Alkenyl and alkynyl compounds as inhibitors of factor Xa
    Patent number: 6545054
    Abstract: Alkenyl and alkynyl compounds as potent and highly selective inhibitors of factor Xa isolated or assembled in the prothrombinase complex and compositions containing such alkenyl and alkynyl compounds are described. Such compounds show selectivity for factor Xa over other proteases of the coagulation (e.g., thrombin, fvIIa, flXa) or the fibrinolytic cascades (e.g., plasminogen activators, plasmin). Methods for using such alkenyl and alkynyl compounds as diagnostic or therapeutic agents for prevention or treatment of a condition in a mammal characterized by undesired coagulation disorders, such as thrombosis, are also described.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: April 8, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Yonghong Song, Robert M. Scarborough, Bing-Yan Zhu
  • Inhibitors of factor Xa
    Patent number: 6545055
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 8, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Ting Su, Zhaozhong Jon Jia, Robert M. Scarborough, Yonghong Song
  • Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20030055244
    Abstract: Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis
    Type: Application
    Filed: April 26, 2002
    Publication date: March 20, 2003
    Inventors: Robert M. Scarborough, Mukund Mehrotra, Anjali Pandey, Mark Smyth
  • Inhibitors of factor Xa
    Patent number: 6534535
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of formula (I) below: are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: March 18, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Robert M. Scarborough, Lane Clizbe, Brandon Doughan, Zhaozhong Jon Jia, Kim Kane-Maguire, Charles Marlowe, Yonghong Song, Ting Su, Willy Teng, Penglie Zhang
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6528534
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: March 4, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • Selective factor Xa inhibitors
    Patent number: 6525076
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: February 25, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
    Publication number: 20030018184
    Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.
    Type: Application
    Filed: April 23, 2002
    Publication date: January 23, 2003
    Applicant: COR THERAPEUTICS, INC.
    Inventors: Johan Sundelin, Robert M. Scarborough
  • Nitrogen containing heterocyclic quinoline compounds
    Publication number: 20030004158
    Abstract: The present invention relates to nitrogen-containing heterocyclic quinoline compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. More particularly, the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Application
    Filed: March 8, 2002
    Publication date: January 2, 2003
    Inventors: Robert M. Scarborough, Anjali Pandey
  • Isoquinolone inhibitors of factor Xa
    Patent number: 6469026
    Abstract: Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: October 22, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Charles K. Marlowe, Wenhao Li, Ting Su, Robert M. Scarborough
  • Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
    Publication number: 20020091130
    Abstract: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.
    Type: Application
    Filed: January 8, 2002
    Publication date: July 11, 2002
    Inventors: James Kanter, Anjali Pandey, James Robinson, Robert M. Scarborough
  • Inhibitors of factor Xa
    Publication number: 20020091116
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: February 28, 2001
    Publication date: July 11, 2002
    Inventors: Bing-Yan Zhu, Zhaozhong Jon Jia, Wenrong Huang, Yonghong Song, James Kanter, Robert M. Scarborough
  • Platelet ADP receptor inhibitors
    Publication number: 20020077486
    Abstract: Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 2, 2001
    Publication date: June 20, 2002
    Inventors: Robert M. Scarborough, Hans-Michael Jantzen, Wolin Huang, David M. Sedlock, Charles K. Marlowe, Kim A. Kane-MaGuire
  • Indole and benzimidazole inhibitors of factor Xa
    Publication number: 20020072530
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: February 1, 2001
    Publication date: June 13, 2002
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
    Publication number: 20020068745
    Abstract: The present invention relates to derivatives and analogues of adenine, which inhibit adenylyl cyclase activity. The present invention also relates to a method of preventing and inhibiting a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amount of a compound according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a patient's fibroproliferative vasculopathy such as chronic allograft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of adenylyl cyclase activity and a method for treating congestive heart failure.
    Type: Application
    Filed: November 20, 2001
    Publication date: June 6, 2002
    Inventors: Daniel Levy, Charles Marlowe, Kim Kane-Maguire, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6399627
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Cor Therapeutics, Inc.
    Inventors: Yonghong Song, Bing-Yan Zhu, Robert M. Scarborough, Lane Clizbe, Zhaozhong Jon Jia, Ting Su, Willy Teng
  • Bivalent phenylene inhibitors of factor Xa
    Publication number: 20020065303
    Abstract: Novel compounds of general formula I: 1
    Type: Application
    Filed: February 1, 2001
    Publication date: May 30, 2002
    Inventors: Bing-Yan Zhu, Robert M. Scarborough